

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER ENDED 30 JUNE 2013

PART I		Quarter Ended			Rs. In Million
Sr.No.	Particulars	30-06-2013	31-03-2013	30-06-2012	Year Ended
		Unaudited	Audited	Unaudited	31-03-2013
					Audited
1	Manufacturing Sales (Net of Excise Duty)	149.31	152.35	138.09	618.08
	Trading Sales	11.13	17.89	0.34	32.96
	Net Sales/ Income from Operations	160.44	170.24	138.43	651.04
2	Total Expenses	115.19	140.03	97.23	470.93
	(a) Cost of material Consumed	23.47	27.55	31.38	147.15
	(b) Purchases of Stock in Trade	10.42	14.41	0.77	31.76
	(c) Change in inventories	-6.84	8.88	-3.62	-24.64
	(d) Employee Benefits exp.	23.40	25.78	18.54	90.62
	(e) Depreciation	9.37	9.58	9.54	43.95
	(f) Other exp.-Mfg.	28.25	24.47	20.70	93.48
	(g) Other exp.-Selling, General & Admn.Exp.	27.12	29.36	19.92	88.61
3	Profit From Operations before other income finance cost, & exceptional items	45.25	30.21	41.20	180.11
4	Other Income	0.28	1.76	0.25	2.34
5	Profit from ordinary activities before finance cost & exceptional items	45.53	31.97	41.45	182.45
6	Finance cost	9.22	9.04	6.46	32.18
7	Profit from ordinary activities after finance cost but before exceptional items	36.31	22.93	34.99	150.27
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit from ordinary activities before tax	36.31	22.93	34.99	150.27
10	Tax Expenses	16.49	2.89	13.98	53.37
11	Net Profit from ordinary activities after tax	19.82	20.04	21.01	96.90
12	Extraordinary Item	0.00	0.00	0.00	0.00
13	Net Profit for the Period	19.82	20.04	21.01	96.90
14	Paid-up equity share capital	85.07	85.07	56.71	85.07
15	Reserves & Surplus	-	-	-	593.68
16	EPS (Rs.) (not annualised) - Basic & Diluted	2.33	2.36	3.70	13.44
PART II					
A PARTICULARS OF SHARE HOLDING					
1	Public shareholding:				
	- Number of Share	3985716	3985716	2619624	3985716
	- % of Shareholding	46.85	46.85	46.19	46.85
2	Promoters and Promoter group shareholding				
a)	Pledged / Encumbered				
	- Number of shares	Nil	Nil	Nil	Nil
	- percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the Company)	Nil	Nil	Nil	Nil
b)	Non- encumbered				
	- Number of shares	4521084	4521084	3051576	4521084
	- percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the Company)	53.15	53.15	53.81	53.15
B INVESTOR COMPLAINTS FOR THE QUARTER ENDED 30-06-2013					
	Pending at the beginning of the quarter		NIL		
	Received during the quarter		1		
	Disposed of during the quarter		1		
	Remaining unresolved at the end of the quarter		NIL		

Hester Biosciences Limited

PUSHPAK, 1st Floor, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad 380006, Gujarat, India
 Ph +91 (79) 2644 5107
 Fax +91 (79) 2644 5105
 www.hester.in
 mail@hester.in



REPORT ON SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED				Rs. In Million
Sr. No.	Particulars	Quarter Ended		Year Ended
		30-06-2013	31-03-2013	31-03-2013
		Unaudited	Audited	Audited
1	Segment Revenue			
	a. Poultry Vaccine	150.65	154.34	138.43
	b. Large Animal Health Product	9.79	15.90	0.00
	Total Income from Operations(Net)	160.44	170.24	138.43
2	Segment Results(Profit before Finance Cost, Exceptional Items and Taxes)			
	a. Poultry Vaccine	48.87	32.44	41.45
	b. Large Animal Health Product	-3.34	-0.47	0.00
	Total	45.53	31.97	41.45
	a. Finance Costs	9.22	9.04	6.46
	b. Exceptional Items	0.00	0.00	0.00
	c. Other unallocable expenditure/(income) [Net]	0.00	0.00	0.00
	Profit before Tax	36.31	22.93	34.99
3	Segment Capital Employed			
	a. Poultry Vaccine	638.90	650.09	586.72
	b. Large Animal Health Product	30.45	23.82	0.00
	c. Unallocated Capital Employed	31.49	30.83	26.71
	Total	700.84	704.74	613.43

Notes :

1. The Board of Directors have approved the aforesaid working result at their meeting held on 14th August, 2013 after reviewed by the Audit Committee of the Company.
2. Segment wise reporting as defined in Accounting Standard (AS-17) is given seperately.
3. Provision for taxation includes Current Tax of Rs. 19.86 million including deferred Tax of Rs. (3.37) million for the quarter as per AS-22.
4. The Auditors of the Company have carried out a "Limited Review" for the said Financial Results.
5. The figures have been re-grouped / rearranged wherever necessary.

Place: Ahmedabad
Date: 14.08.2013

By order of the Board

Rajiv Gandhi
CEO & Managing Director

Hester Biosciences Limited

PUSHPAK, 1st Floor, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad 380006, Gujarat, India
Ph +91 (79) 2644 5107
Fax +91 (79) 2644 5105

www.hester.in
mail@hester.in



**The Board of Directors
Hester Biosciences Ltd
Ahmedabad.**

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of Standalone Un-audited Financial Results of **Hester Biosciences Ltd.**, having its registered office at 1st Floor, Pushpak, Panchvati Circle, Off. C. G. Road, Ahmedabad : 380 006 for the quarter ended 30-06-2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe the accompanying statement of un-audited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Ahmedabad

Date : 14th August , 2013



**For Shah Narielwala & Co.
Chartered Accountants
FRN:109708W**

Naishank H. Shah
**Partner
Mem. No. 042323**



Ahmedabad
14.08.2013

PRESS RELEASE

Q1 Results

Hester has reported a turnover of Rs. 160.44 million in Q1 ended 30.6.2013 as compared to Rs. 138.43 million for the previous corresponding period.

Net Profit before tax for Q1 is recorded at Rs. 36.31 million against Rs. 34.99 million for the previous corresponding period.

Rajiv Gandhi
CEO & Managing Director
Hester Biosciences Limited
www.hester.in
rajiv.gandhi@hester.in

Hester Biosciences Limited

PUSHPAK, 1st Floor, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad 380006, Gujarat, India.

Ph +91 (79) 2644 5107

Fax +91 (79) 2644 5105

www.hester.in

mail@hester.in